These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Phase II evaluation of mitoxantrone in patients with bronchogenic carcinoma: a Southeastern Cancer Study Group trial. Kramer BS; Gams R; Birch R; Einhorn L; Buchanan R Cancer Treat Rep; 1984 Oct; 68(10):1295-6. PubMed ID: 6525601 [No Abstract] [Full Text] [Related]
8. Phase II clinical trial of diaziquone in bronchogenic carcinoma. Chiuten DF; Umsawasdi T; Dhingra HM; Murphy WK; Spitzer G; Carr DT; Bodey GP; Valdivieso M Cancer Treat Rep; 1985; 69(7-8):921-2. PubMed ID: 4016800 [No Abstract] [Full Text] [Related]
9. Phase II trial of bisantrene for unresectable non-small cell bronchogenic carcinoma: an Illinois Cancer Council study. McGuire WP; Blough RR; Cobleigh MA; Johnson CM; Kukla LJ; Lad TE; Lanzotti VJ; Stiff PJ; Zawila P Cancer Treat Rep; 1983 Sep; 67(9):841-2. PubMed ID: 6883363 [No Abstract] [Full Text] [Related]
10. Phase II study of divided-dose vinblastine in non-small cell bronchogenic carcinoma. Schulman P; Budman DR; Vinciguerra V; Weiselberg L; Abrams S; Degnan T Cancer Treat Rep; 1982 Jan; 66(1):171-2. PubMed ID: 7053253 [TBL] [Abstract][Full Text] [Related]
11. The dosage regimen of levamisole in cancer: is it related to efficacy and safety? Amery WK; Butterworth BS Int J Immunopharmacol; 1983; 5(1):1-9. PubMed ID: 6341264 [No Abstract] [Full Text] [Related]
12. [Phase II trial with cystemustine (60 mg/m2) in advanced or metastatic pretreated lung carcinoma]. Rebattu P; Coudert B; Schneider M; Ouabdesselam R; Lentz M; Hanauske A; Chevallierdagger B; Fumoleau P; Chollet P Rev Pneumol Clin; 2000 Jun; 56(3):200-3. PubMed ID: 10880946 [TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy and combined chemoradiotherapy procedures in bronchial carcinoma]. Wolf M; Havemann K Internist (Berl); 1994 Aug; 35(8):740-50. PubMed ID: 7525503 [No Abstract] [Full Text] [Related]
14. Phase II study of doxorubicin and mitomycin in non-small cell bronchogenic carcinoma. Coates AS; Fox RM; Woods RL; Levi JA; Tattersall MH Cancer Treat Rep; 1982 Jan; 66(1):177-8. PubMed ID: 7053255 [TBL] [Abstract][Full Text] [Related]
15. Phase II trial of mitomycin, vinblastine, and cisplatin (MVP) in non-small cell bronchogenic carcinoma. Schulman P; Budman DR; Weiselberg L; Vinciguerra V; Degnan TJ Cancer Treat Rep; 1983 Oct; 67(10):943-5. PubMed ID: 6684988 [TBL] [Abstract][Full Text] [Related]
16. Treatment of Brugia malayi infection with levamisole. O'Holohan DR; Zaman V J Trop Med Hyg; 1974 May; 77(5):113-5. PubMed ID: 4835326 [No Abstract] [Full Text] [Related]
17. Phase II evaluation of acivicin in lung cancer: a Southeastern Cancer Study Group Trial. Kramer BS; Birch R; Greco A; Prestridge K; Johnson R Cancer Treat Rep; 1986 Aug; 70(8):1031-2. PubMed ID: 3524833 [No Abstract] [Full Text] [Related]
18. A double-blind comparison of high and low doses of levamisole in rheumatoid arthritis. Pinals RS; Robertson F; Blechman WJ J Rheumatol; 1981; 8(6):949-51. PubMed ID: 7328569 [TBL] [Abstract][Full Text] [Related]
19. Immunopotentiation with levamisole in resectable bronchogenic carcinoma: a double-blind controlled trial; Study Group for Bronchogenic Carcinoma. Br Med J; 1975 Aug; 3(5981):461-4. PubMed ID: 1098727 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant levamisole in the treatment of patients with resectable lung cancer. Amery WK Ann Clin Res; 1980; 12 Suppl 27():1-83. PubMed ID: 6999969 [No Abstract] [Full Text] [Related] [Next] [New Search]